Analyst Consensus ?
ConsensusHold34 ratings
Bullish1750.0%
Neutral1441.2%
Bearish38.8%
Henry Schein, Inc. · HSIC · FY2026 Q2 · Calendar Q3 2026
Henry Schein raises 2026 outlook as technology growth broadens
The Q2 analysis supports a constructive but conditional view of Henry Schein's operating trajectory: technology adoption, own-brand products, DSO consolidation, and value-creation initiatives are strengthening the growth mix. The case depends on sustaining margin gains and demand while managing foreign exchange, remeasurement effects, and softer diagnostic or equipment trends.
Reported Before market openNASDAQHealthcare
$9.71B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.27
Consensus $1.24
EPS surprise
+2.4%
Reported versus consensus
Reported revenue
$3.46B
Consensus $3.37B
Revenue surprise
+2.5%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+3.0%
Event window
SPY move
+1.8%
Same window
Abnormal move
+1.2%
Stock minus SPY
Volume
2.5×
Versus trailing sessions
Subsequent drift
-0.7%
Up to 20 sessions
HSICSPY benchmark
Ask FN2 about HSIC FY2026 Q2
Transcript, numbers and history already loaded
Why did HSIC rise 3.0% after beating EPS estimates in FY2026 Q2?What changed in HSIC's guidance and outlook in FY2026 Q2?Give me the bull and bear case for HSIC after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Versus the prior-quarter analysis, guidance sentiment moved from maintained to raised. The current analysis adds stronger evidence around technology-platform adoption, including a record month of new Dentrix Ascend customers, the planned MCP AI layer, and management's clarification that 90% of Henry Schein One revenue is recurring.
Guidance delta
Raised versus the prior quarter's maintained full-year 2026 outlook; the supplied analysis does not provide the revised sales or EPS ranges.
Key takeaways
- Q2 analysis describes strong sales and margin expansion across segments, with internal local-currency sales growth of 4.6%.
- Management highlighted Dentrix Ascend and Henry Schein One, including an upcoming MCP AI layer and recurring technology revenue.
- The value-creation program remains targeted at $200 million of operating-income improvement, with a $125 million run-rate by year-end.
Management priorities
- Expand AI-enabled clinical and operational workflows, including the planned MCP AI layer.
- Improve efficiency through outsourcing, supply-chain software, and portfolio rationalization.
- Use own-brand products, DSO consolidation, and disciplined M&A to support growth.
Follow HSIC with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$87.43Current
$64Low
$87.38Average
$110High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 22, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| BTIG | Buy | Buy | Maintain | Aug 19, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 6, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 5, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 5, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 29, 2026 |
| Mizuho | Neutral | Neutral | Maintain | May 6, 2026 |
| Morgan Stanley | Underweight | Underweight | Maintain | Apr 24, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Apr 8, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Feb 25, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Feb 25, 2026 |
| Barrington Research | Outperform | Outperform | Maintain | Feb 25, 2026 |
| Leerink Partners | Market Perform | Market Perform | Maintain | Feb 24, 2026 |
| Baird | Outperform | Neutral | Upgrade | Feb 23, 2026 |
| Stifel | Hold | Buy | Downgrade | Jul 25, 2025 |
| Jefferies | Hold | Hold | Maintain | Jan 23, 2025 |
| B of A Securities | Buy | Underperform | Upgrade | Jan 6, 2025 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 8, 2023 |
| Goldman Sachs | Neutral | Buy | Downgrade | Jul 21, 2022 |
| CFRA | Hold | Hold | Maintain | May 5, 2020 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Apr 2, 2020 |
| Bank of America | Neutral | Neutral | Maintain | Dec 3, 2019 |
| William Blair | Market Perform | Outperform | Downgrade | Aug 7, 2019 |
| SVB Leerink | Market Perform | Outperform | Downgrade | May 15, 2019 |
| Guggenheim | Buy | Buy | Maintain | Apr 18, 2019 |
| Edward Jones | Sell | Hold | Downgrade | Oct 25, 2018 |
| Stifel Nicolaus | Hold | Hold | Maintain | Aug 7, 2018 |
| Deutsche Bank | Buy | Buy | Maintain | Apr 24, 2018 |
| Leerink Swann | Outperform | Market Perform | Upgrade | Apr 4, 2018 |
| Stephens & Co. | Equal Weight | Equal Weight | Maintain | Nov 28, 2017 |
| Craig-Hallum | Buy | Hold | Upgrade | Nov 7, 2017 |
| RBC Capital | Perform | Sector Perform | Maintain | Sep 19, 2017 |
| PiperJaffray | Overweight | Neutral | Upgrade | Sep 15, 2017 |
| Gabelli & Co. | Buy | Hold | Upgrade | Jan 10, 2017 |
| ISI Group | Underweight | Underweight | Maintain | Jul 12, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $87.43. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| BTIG | David Larsen | $110 | $90.62 | +25.8% | Aug 19, 2026 |
| Barclays | Analyst unavailable | $100 | $89.59 | +14.4% | Aug 6, 2026 |
| Barrington | Michael Petusky | $104 | $89.11 | +19.0% | Aug 5, 2026 |
| UBS | Kevin Caliendo | $94 | $89.11 | +7.5% | Aug 5, 2026 |
| Stifel Nicolaus | Analyst unavailable | $95 | $89.11 | +8.7% | Aug 5, 2026 |
| UBS | Analyst unavailable | $89 | $85.88 | +1.8% | Jul 28, 2026 |
| BMO Capital | Vik Chopra | $85 | $83.22 | -2.8% | Jul 8, 2026 |
| BTIG | Analyst unavailable | $100 | $78.85 | +14.4% | Jun 11, 2026 |
| UBS | Kevin Caliendo | $85 | $74.35 | -2.8% | May 6, 2026 |
| Mizuho Securities | Analyst unavailable | $82 | $74.37 | -6.2% | May 6, 2026 |
| Robert W. Baird | Analyst unavailable | $97 | $74.37 | +10.9% | May 6, 2026 |
| Morgan Stanley | Erin Wright | $64 | $78.22 | -26.8% | Apr 24, 2026 |
| Barrington | Analyst unavailable | $97 | $81.6 | +10.9% | Feb 25, 2026 |
| Leerink Partners | Analyst unavailable | $87 | $83.35 | -0.5% | Feb 24, 2026 |
| Robert W. Baird | Analyst unavailable | $100 | $79.57 | +14.4% | Feb 23, 2026 |
| Mizuho Securities | Steven Valiquette | $81 | $79.98 | -7.4% | Jan 20, 2026 |
| Barclays | Analyst unavailable | $86 | $72.86 | -1.6% | Dec 8, 2025 |
| Evercore ISI | Analyst unavailable | $90 | $71.68 | +2.9% | Nov 5, 2025 |
| Barrington | Analyst unavailable | $79 | $71.32 | -9.6% | Nov 5, 2025 |
| Evercore ISI | Analyst unavailable | $83 | $69.04 | -5.1% | Aug 26, 2025 |
| Leerink Partners | Michael Cherny | $75 | $70.8 | -14.2% | Jul 14, 2025 |
| Barrington | Michael Petusky | $86 | $66.24 | -1.6% | May 6, 2025 |
| CFRA | Daniel Rich | $67 | $71.1 | -23.4% | Oct 15, 2024 |
| Evercore ISI | Elizabeth Anderson | $74 | $69.3 | -15.4% | Oct 8, 2024 |
| Robert W. Baird | Jeff Johnson | $92 | $70.34 | +5.2% | Jul 22, 2024 |
| Stifel Nicolaus | Jonathan Block | $70 | $64.07 | -19.9% | Nov 13, 2023 |
| Stifel Nicolaus | Jonathan Block | $80 | $73.17 | -8.5% | Jun 17, 2022 |
| Robert W. Baird | Jeff Johnson | $88 | $78.82 | +0.7% | Jun 14, 2022 |
| Barclays | Steven Valiquette | $82 | $77.3 | -6.2% | Aug 4, 2021 |
Track every rating change on HSIC the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationHenry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment.…
Historical context
All HSIC earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
| A Agilent Technologies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +8.7% | +1.7% | Agilent raises outlook after Q3 beat; Ignite drives margin gains |
Latest beats and misses
Who reports nextBeat on EPS
- FPSFY2026 Q4 · September 15, 2026+4.3% EPS+9.5% move
- TCOMFY2026 Q2 · September 15, 2026+22.3% EPS+3.0% move
- KRFY2026 Q2 · September 11, 2026+2.8% EPS+2.7% move
- ADBEFY2026 Q3 · September 10, 2026+0.8% EPS+1.4% move
- ORCLFY2027 Q1 · September 10, 2026+10.3% EPS-1.7% move
- CASYFY2027 Q1 · September 8, 2026+8.7% EPS-14.2% move
Get the HSIC recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-08-04T21:13:06.216398+00:00
- FN2 earnings calendar · 2026-09-09T01:23:14.388487+00:00
- Polygon adjusted daily market bars · 2026-09-22T22:00:52.324347+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-22T22:00:52.321308+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-22. For educational purposes only; not investment advice.